Vita Therapeutics enters licensing agreement with MilliporeSigma

Today, Vita Therapeutics announced they entered a licensing agreement with MilliporeSigma to advance their cell therapy program to treat LGMD2A/R1. This agreement allows Vita to utilize MilliporeSigma’s CRISPR gene editing patents to insert a functional copy of the CAPN3 gene into patient-derived stem cells. This is a critical step in the development of a cell therapy that can be transplanted into the body to restore muscle function.

Click here for more information